Pharmacometrics
Services

Matt advances the integration of published clinical outcomes data into development decisions and commercial and regulatory strategy via model-based meta-analysis (MBMA). Matt works closely with clinical development teams to ensure MBMA is leveraged for optimal impact when making the most critical decisions.

Rik de Greef is a Senior VicePresident of Global Quantitative Science Services at Certara. Rik was trained as a PK-PD scientist at Leiden University, The Netherlands. Over the years, Rik has taken on roles with increasing responsibilities within Organon and its successor companies Schering-Plough and Merck/MSD.

Stephen provides advanced pharmacometrics guidance for complex drug development challenges.

Adekemi specializes in in pharmacometric strategy and analyses (including population PK, PK/PD, efficacy and safety exposure-response, and concentration-QTc modeling) to support regulatory filings, study design, and general drug development.

Dr. Cheung has over a decade of experience working in the pharmaceutical industry at AstraZeneca, with her role as Senior Pharmacometrician and Project manager of AZ Paediatric working group. She obtained her Ph.D. from the University of Manchester.

Paul excels in pharmacometrics modeling, project leadership, and client relations, focusing on decision support and regulatory filings across various therapeutic areas.

JF has 25 years of experience performing PK, PK/PD and exposure-response analyses to support dosing rationale in various therapeutic areas.  Specialties include oncology, rare diseases and pediatric populations.

Mirjam, a pharmacometrics consultant, serves as the US Lead for Pharmacometrics, Division II, at Certara. With expertise spanning various modalities, including complex biologics, she specializes in Cell and Gene Therapy.